论文部分内容阅读
背景及目的:HORIZONS-AMI研究已经发现,行PCI的急性ST段抬高的心肌梗死(STEMI)患者给予凝血酶抑制剂比伐卢定治疗,与肝素加糖蛋白Ⅱb/Ⅲa抑制剂(GPI)治疗相比,30天时的大出血并发症以及实际不良反应事件显著降低。本研究又对用药1年后的疗效进行了评价。
BACKGROUND AND AIM: The HORIZONS-AMI study has found that patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent PCI were given bivalirudin, a thrombin inhibitor, and heparin plus glycoprotein IIb / IIIa inhibitor (GPI) Significant reductions in major bleeding complications and actual adverse events at 30 days were observed. This study again evaluated the efficacy of the drug one year later.